3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
2
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
3
Gastrointestinal
2
Lymphoid
1
CNS
1
Conditions
Lymphoma, Follicular
200
Lymphoma
199
Lymphoma, Non-Hodgkin
167
Leukemia, Lymphocytic, Chronic, B-Cell
166
Lymphoma, Large B-Cell, Diffuse
163
Precursor Cell Lymphoblastic Leukemia-Lymphoma
154
Leukemia
89
Hodgkin Disease
89
Lymphoma, Mantle-Cell
80
Lymphoma, B-Cell, Marginal Zone
66
Burkitt Lymphoma
65
Leukemia, Myeloid, Acute
55
Multiple Myeloma
52
Lymphoma, Large-Cell, Immunoblastic
48
Recurrence
44
Neoplasms
38
Myelodysplastic Syndromes
38
Lymphoma, T-Cell, Cutaneous
36
Mycosis Fungoides
30
Lymphoma, Large-Cell, Anaplastic
30
Waldenstrom Macroglobulinemia
28
Leukemia, Myeloid, Chronic-Phase
28
Myeloproliferative Disorders
27
Lymphoma, B-Cell
27
Leukemia, Myeloid, Accelerated Phase
27
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
26
Sezary Syndrome
25
Leukemia, Biphenotypic, Acute
25
Blast Crisis
24
Primary Myelofibrosis
22
Interventions
duvelisib
1
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hereditary Sensory and Autonomic Neuropathies
×
Lymphoid
×
Clear all
NCT02204982
2023-09-28
DYNAMO + R
SecuraBio
Phase 3
Terminated
13 enrolled
10 charts
1 FDA